The role of cytochrome bc<sub>1</sub> inhibitors in future tuberculosis treatment regimens.

There was a trend towards improvement of both the bacterial burden (BPaLJ: 0.95 ± 1.1 versus BPaL: 2.06 ± 1.3 log 10 CFU lung −1 , p = 0.04) and a quantifiable improvement in relapse rates, that failed to reach statistical significance within the limitations of this trial design (50% versus 89%, p > 0.05).

also in 6,035 other papers